Abstract:Mutations in ion channel genes can cause a diverse group of phenotypes and play important roles in the filed of monogenic neurological diseases [[1]Rajakulendran S. Kaski D. Hanna M.G. Neuronal P/Q-type calcium channel dysfunction in inherited disorders of the CNS.Nat Rev Neurol. 2012; 8: 86-96Crossref PubMed Scopus (103) Google Scholar]. With the application of Next-generation sequencing, more and more genetic and clinical heterogeneity in monogenic neurological diseases was reported, which improved our understanding of the pathophysiologic mechanisms in different monogenic neurological diseases. Herein, we report a girl presenting with intractable absence epilepsy, who had a dramatic response to pyridoxine. Using a panel containing 153 epilepsy-related genes based on Next-generation sequencing, a de novo CACNA1A mutation was found coincidentally. Our report expands the clinical spectrum of CACNA1A-related disorders and the genetic spectrum of pyridoxine dependent epilepsy (PDE). The patient was born at term after an unremarkable pregnancy and had nearly normal early psychomotor development, although the parents reported that the patient could not run fast like other normal children or speak smoothly. At the age of 3 years, she presented blank episode lasting for 2–3s several times per day. The postural tone was not lost and she was able to resume normal activities immediately. Absence epilepsy was considered after attending to a local hospital and valproic acid (VPA) was used (200 mg per day). However, no improvement was observed and the absence seizure still occured 2–3 times per day. At the age of 5 years, the patient came to our hospital. VPA (500 mg per day) and lamotrigine (LTG) (150 mg per day) were used and the frequency of absence seizure decreased. It only happened when the patient's temperature was above 38 °C. At the age of 6 years, the frequency of absence seizure increased without obvious inducement. It occurred 20–30 times per day, accompanying with partial seizures for 3 times in one year, which all presented as right upper limb hold up, eyes looked toward right side and unconsciousness for about 1 min. No episodic attack of ataxia was complained. An ataxic gait was observed, which was considered as antiepileptic drugs (AEDs) induced ataxia at first. On EEG examination, a typical 2.5–3 Hz spike–wave was observed (Fig. 1A). The diagnosis of absence epilepsy was made based on clinical features and EEG result. Brain MRI at the age of 3 years revealed hippocampal sclerosis on the left side and no obvious cerebellar atrophy. At the age of 10 years, cerebellar atrophy was observed on the sagittal view in the brain MRI (Supplemental data 1). Metabolic tests of blood and urine were all normal, which included normal level of proline in blood. Other blood tests including alkaline phosphatase and Ca2+ were all within normal range. As pyridoxine was proposed in some intractable epilepsy, 500 mg pyridoxine (Vitamin B6, 20 mg/kg) daily was added to current treatment of 750 mg (30 mg/kg) VPA and 150 mg (6 mg/kg) LTG daily. A dramatic improvement was observed that the frequency of absence seizure was less than 10 times on the first day and no absence seizure was observed on the next five days. The pyridoxine withdraw test was positive as the frequency of absence seizure increased (about 30–40 times per day) when we reduced the dose of pyridoxine. After the use of pyridoxine, the background of EEG was also better than that before the use of pyridoxine (Fig. 1B and C). The patient was discharged with oral drugs containing 750 mg (30 mg/kg) pyridoxine, 500 mg (20 mg/kg) VPA and 50 mg (2 mg/kg) LTG daily. In the next year, with oral drugs containing 200 mg (7.4 mg/kg) pyridoxine, 500 mg (18 mg/kg) VPA and 50 mg (1.9 mg/kg) LTG daily, she only had absence seizure for 2–3 times per day and one generalized tonic–clonic seizure in this year. The ataxia did not improve or progress and no episodic progress of ataxia was complained. Using a panel containing 153 epilepsy-related genes (Supplemental data 3) based on Next-generation sequencing, a heterozygous missense variant c. 410A>G (p. E137G) in CACNA1A gene was detected in this patient. This variant was further confirmed by Sanger sequencing and not detected in either of the healthy parents, which indicated that this variant was de novo (Supplemental data 2). According to the standards and guidelines of ACMG and MacArthur et al., this variant was evaluated as pathogenic mutation (Supplemental data 4). No pathogenic variant in genes (ALDH7A1, PNPO and PIGV were contained in the panel) responsible for PDE was detected in this patient. Although other two genes (TNSALP and ALDH4A1) responsible for PDE were not sequenced, the normal level of proline and alkaline phosphatase did not support this patient had their responsible phenotypes of hypophosphatasia and hyperprolinemia type 2 [[2]Stockler S. Plecko B. Gospe Jr., S.M. Coulter-Mackie M. Connolly M. van Karnebeek C. et al.Pyridoxine dependent epilepsy and antiquitin deficiency: clinical and molecular characteristics and recommendations for diagnosis, treatment and follow-up.Mol Genet Metab. 2011; 104: 48-60Crossref PubMed Scopus (214) Google Scholar]. Based on these clinical and genetic studies, we concluded that the mutation c. 410A>G (p. E137G) in CACNA1A gene was the causative mutation in this patient. Mutations in CACNA1A have complicated phenotypic heterogeneity, and mainly cause three allelic disorders: episodic ataxia type 2 (OMIM: 108500), familial hemiplegic migraine type 1 (OMIM: 141500) and spinocerebellar ataxia type 6 (OMIM: 183086) [[1]Rajakulendran S. Kaski D. Hanna M.G. Neuronal P/Q-type calcium channel dysfunction in inherited disorders of the CNS.Nat Rev Neurol. 2012; 8: 86-96Crossref PubMed Scopus (103) Google Scholar]. Epilepsy was reported in about 7% patients of episodic ataxia type 2 [[3]Rajakulendran S. Graves T.D. Labrum R.W. Kotzadimitriou D. Eunson L. Davis M.B. et al.Genetic and functional characterisation of the P/Q calcium channel in episodic ataxia with epilepsy.J Physiol. 2010; 588: 1905-1913Crossref PubMed Scopus (69) Google Scholar]. Absence epilepsy with a 3 Hz spike–wave EEG pattern was reported as the core symptom in several patients with mutations in CACNA1A. The clinical phenotype of absence epilepsy with ataxia (AEA) was proposed in these patients [[4]Imbrici P. Jaffe S.L. Eunson L.H. Davies N.P. Herd C. Robertson R. et al.Dysfunction of the brain calcium channel CaV2. 1 in absence epilepsy and episodic ataxia.Brain. 2004; 127: 2682-2692Crossref PubMed Scopus (193) Google Scholar]. According to the clinical features and EEG result of this patient, a diagnosis of AEA should be considered. To our knowledge, there were a total of ten patients with CACNA1A gene mutations experienced absence seizure reported. We reviewed these patients' clinical phenotypes, EEG, brain MRI and drug response of absence seizure (Table 1). The response to AEDs in these patients with absence seizure was variable from "seizure-free with VPA and LTG" and "successively treated with VPA, topiramate and levetiracetam" to intractable absence seizure even with two or three conventional AEDs (like VPA and ethosuximide) for absence seizure. It seems that the absence seizure was not easy to be controlled as this type of seizure used to be. This patient presented frequent absence seizure, which was intractable to several AEDs (VPA and LTG). As pyridoxine was proposed in some intractable epilepsy, pyridoxine was used in this patient and a dramatic response was observed clinically and electroencephalographically. The positive result of the pyridoxine withdraw test supported the pyridoxine dependence of the absence epilepsy in this patient.Table 1Patients with CACNA1A mutations presenting absence seizure.ReferencePatient IDCACNA1A mutationEEGMRIDrugs for absence seizureOther phenotypesJouvenceau et al.Noc.5733C>T, p.R1820XGeneralized polyspike and waveNormalNo response to LTGGTCS, EA, cognitive impairmentImbrici et al. [4]Imbrici P. Jaffe S.L. Eunson L.H. Davies N.P. Herd C. Robertson R. et al.Dysfunction of the brain calcium channel CaV2. 1 in absence epilepsy and episodic ataxia.Brain. 2004; 127: 2682-2692Crossref PubMed Scopus (193) Google ScholarII:6c.439G>A, p.E147KGeneralized 3 Hz spike–waveCerebellar vermian atrophySymptoms remitted on acetazolamide and CBZEA, AEDs induced cerebellar ataxia.III:3c.439G>A, p.E147KGeneralized 3 Hz spike–waven.a.No response to CZP and PHTEA, cognitive impairment, AEDs induced cerebellar ataxia.I:2c.439G>A, p.E147KGeneralized 3 Hz spike–waven.a.n.a.EAStrupp et al.Patient 2c.5733C>T, p.R1820Xn.a.Slight cerebellar atrophy (vermis)n.a.EALabrum et al.F6Deletion of exons 39–47Generalized 3 Hz spike–waveCerebellar atrophy, in particular the vermisn.a.EARajakulendran et al. [3]Rajakulendran S. Graves T.D. Labrum R.W. Kotzadimitriou D. Eunson L. Davis M.B. et al.Genetic and functional characterisation of the P/Q calcium channel in episodic ataxia with epilepsy.J Physiol. 2010; 588: 1905-1913Crossref PubMed Scopus (69) Google Scholar6c.3313G>A, p. G1105SGeneralized 3 Hz spike–waven.a.n.a.EA, learning difficultiesJung et al.III:1c.1063dupG, p. V355Gfs*32Generalized 3 Hz spike–waveSevere cerebellar vermian atrophySeizure-free with VPA and LTGMigraineDamaj et al.F1-4.1c.3832C>T, p.R1278XDiffuse slowing, generalized theta bursts interspersed with spikes, bi-occipital spikesHippocampalasymmetry (L > R)Successively treated with VPA TPM and LEV.EA, GTCS, global developmental delayF2-4.1c.2867_2869del, p.R957Dfs113Generalized 3 Hz spike–waveNormalRefractory to VAP and ESM but partially responsive to VPA and LEVEA, global developmental delay, learning difficulties, ADHDADHD: attention deficit hyperactivity disorder; AEDs: antiepileptic drugs; CBZ, carbamazepine; CZP, clonazepam; EA: episodic ataxia; ESM: ethosuximide; F: family; GTCS: generalized tonic-clonic seizure; LEV, levetiracetam; LTG: lamotrigine; n.a.: not available; PHT, phenytoin; PMT, primidome; TPM, topiramate; VPA, valproic acid. Open table in a new tab ADHD: attention deficit hyperactivity disorder; AEDs: antiepileptic drugs; CBZ, carbamazepine; CZP, clonazepam; EA: episodic ataxia; ESM: ethosuximide; F: family; GTCS: generalized tonic-clonic seizure; LEV, levetiracetam; LTG: lamotrigine; n.a.: not available; PHT, phenytoin; PMT, primidome; TPM, topiramate; VPA, valproic acid. PDE is characterized by intractable seizures that are not controlled with conventional AEDs but that respond clinically and electroencephalographically to pharmacologic doses of pyridoxine [[2]Stockler S. Plecko B. Gospe Jr., S.M. Coulter-Mackie M. Connolly M. van Karnebeek C. et al.Pyridoxine dependent epilepsy and antiquitin deficiency: clinical and molecular characteristics and recommendations for diagnosis, treatment and follow-up.Mol Genet Metab. 2011; 104: 48-60Crossref PubMed Scopus (214) Google Scholar]. Autosomal recessive inherited mutations in ALDH7A1 gene were the main genetic defects of PDE. Four other autosomal recessive conditions with seizures responsive to pyridoxine or its vitamers are known: pyridoxal phosphate responsive epileptic encephalopathy (OMIM: 610090, PNPO gene), neonatal/infantile hypophosphatasia (OMIM: 241500, TNSALP gene), familial hyperphosphatasia (OMIM: 239300, PIGV gene) and hyperprolinemia type 2 (OMIM: 239510, ALDH4A1 gene). In this patient, no mutation of ALDH7A1, PNPO and PIGV genes was detected and the tests in blood and urine did not support a clinical diagnosis of neonatal/infantile hypophosphatasia or hyperprolinemia type 2. However, it is a limitation that we did not sequence TNSALP and ALDH4A1 genes. Although some AEA patients with CACNA1A mutations reported intractable absence seizure, pyridoxine was not used in these patients. We suggested that pyridoxine could be tried as the choice in such patients. Our report expands the clinical spectrum of CACNA1A-related disorders and the genetic spectrum of PDE and more observation was needed to get a more reliable conclusion. The authors declare no competing financial interests. We are indebted to the patient and parents for their generous participation in this study. This study was supported by the National Natural Science Foundation of China (Proj. No. 81600850, 81571089 and 81371266). The authors have stated that they had no interests which might be perceived as posing a conflict or bias. The following is Supplementary data to this article: Download .docx (1.09 MB) Help with docx files Response to pyridoxine in CACNA1A epilepsy-ataxia does not imply a causal effectSeizure - European Journal of EpilepsyVol. 91PreviewDu and colleagues report a case of a 10-year-old girl with refractory absence seizures and chronic ataxia, left sided hippocampal sclerosis at six years, followed by cerebellar atrophy at 10 years[1], attributed to a de novo CACNA1A missense variant c.410A>G (p.Glu137Gly). Their patient responded to oral pyridoxine adjunctive to sodium valproate and lamotrigine, with acute abolition of absences but no impact on ataxia. The authors suggested that pyridoxine may be a useful therapy in CACNA1A related disorders and that their patient expanded the spectrum of pyridoxine dependent epilepsies (PDEs). Full-Text PDF Open Archive

Myeloperoxidase as a biomarker in acute coronary syndrome: beware of the pitfalls.

CAD mutations and uridine-responsive epileptic encephalopathy

Dramatic Response to Pyridoxine in a Girl with Absence Epilepsy with Ataxia Caused by a De Novo CACNA1A Mutation.

Autosomal Dominant Sleep-Related Hypermotor Epilepsy Associated with a Novel Mutation of KCNT1.

A Patient with CAD Deficiency Responsive to Uridine and Literature Review

Case Report: Rapid Treatment of Uridine-Responsive Epileptic Encephalopathy Caused by CAD Deficiency

Novel CAD gene mutations in a boy with developmental and epileptic encephalopathy 50 with dramatic response to uridine therapy: a case report and a review of the literature

Case report: Childhood epilepsy and borderline intellectual functioning hiding an AADC deficiency disorder associated with compound heterozygous DDC gene pathogenic variants

Expanding the clinical and genetic spectrum of CAD deficiency: an epileptic encephalopathy treatable with uridine supplementation

AARS and CACNA1A mutations: diagnostic insights into a case report of uncommon epileptic encephalopathy phenotypes in two siblings

Biallelic CACNA1A variants: Review of literature and report of a child with drug‐resistant epilepsy and developmental delay

Characteristics of Developmental and Epileptic Encephalopathy Associated with PACS2 p.Glu209Lys Pathogenic Variant—Our Experience and Systematic Review of the Literature

Cerebral folate deficiency: a treatable cause of late deterioration in epilepsy with developmental delay

Case report: Diagnosis of a patient with Sifrim-Hitz-Weiss syndrome, development and epileptic encephalopathy-14, and medium chain acyl-CoA dehydrogenase deficiency

A Treatable Genetic Disease Caused by CAD Mutation

Deficiency of Adenosine Deaminase 2 in Adult Siblings: Many Years of a Misdiagnosed Disease with Severe Consequences

SCN8A-related developmental and epileptic encephalopathy with ictal asystole requiring cardiac pacemaker implantation

Seizure and movement disorder in CACNA1E developmental and epileptic encephalopathy: Two sides of the same coin or same side of two different coins?

High-resolution molecular genomic autopsy reveals complex sudden unexpected death in epilepsy risk profile

[Early Infantile Epileptic Encephalopathy Caused by PACS2 Gene Variation: Three Cases Report and Literature Review].

Importance of targeted next-generation sequencing in pediatric patients with developmental epileptic encephalopathy